Diabetes-induced changes in specific lipid molecular species in rat myocardium.
Intrinsic cardiac dysfunction during the diabetic state has been causally linked to changes in myocardial lipid metabolism. However, the precise alterations in the molecular species of myocardial polar and non-polar lipids during the diabetic state and their responses to insulin have not been investigated. Herein we demonstrate four specific alterations in rat myocardial lipid molecular species after induction of the diabetic state by streptozotocin treatment: (i) a massive remodelling of triacylglycerol molecular species including a >5-fold increase in tripalmitin mass and a 60% decrease in polyunsaturated triacylglycerol molecular species mass (i.e. triacylglycerols containing at least one acyl residue with more than two double bonds); (ii) a 46% increase in myocardial phosphatidylinositol mass; (iii) a 44% increase in myocardial plasmenylethanolamine mass and (iv) a 22% decrease in 1-stearoyl-2-arachidonoyl phosphatidylethanolamine content. Each of the changes in phospholipid classes, subclasses and individual molecular species were prevented by insulin treatment after induction of the diabetic state. In sharp contrast, the alterations in triacylglycerol molecular species were not preventable by peripheral insulin treatment after induction of the diabetic state. These results segregate diabetes-induced alterations in myocardial lipid metabolism into changes that can be remedied or not by routine peripheral insulin treatment and suggest that peripheral insulin therapy alone may not be sufficient to correct all of the metabolic alterations present in diabetic myocardium.
Han
X
X
Division of Bioorganic Chemistry and Molecular Pharmacology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8020, St. Louis, MO 63110, USA.
Abendschein
D R
DR
Kelley
J G
JG
Gross
R W
RW
D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D002849:Chromatography, Gas; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D008297:Male; D013058:Mass Spectrometry; D009206:Myocardium / Q000378:metabolism*; D010714:Phosphatidylethanolamines / Q000378:metabolism; D010716:Phosphatidylinositols / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism*; D010955:Plasmalogens / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin / Q000494:pharmacology; D013997:Time Factors; D014280:Triglycerides / Q000378:metabolism
D010714:Phosphatidylethanolamines; D010716:Phosphatidylinositols; D010743:Phospholipids; D010955:Plasmalogens; D014280:Triglycerides; C020791:phosphatidal ethanolamines; D016718:Arachidonic Acid; D013311:Streptozocin; C005859:tripalmitin